If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-08. Numbers and descriptions here follow the published literature rather than marketing material.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
The 'Dunkin' Donut' with a handle fashioned on it was discontinued in 2003 (except in Singapore) because it was hand-cut and uneconomical compared to machine-cut doughnuts. In 2004, the company's headquarters were relocated to Canton, Massachusetts. In December 2005, Dunkin' Donuts and Baskin-Robbins (by then, operating under the name Dunkin' Brands) were sold to a private equity consortium of Bain Capital, Carlyle Group, and Thomas H. Lee Partners for $2.4 billion. By 2010, Dunkin' Donuts' global sales were $6 billion. In June 2013, Dunkin' Donuts unveiled a new store design, the brand's first in almost seven years. The Dunkin' Donuts location in Natick, Massachusetts launched a program to test the concept of curbside pickup in December 2016. In January 2018, Dunkin' Donuts started opening new concept locations, beginning in Quincy, featuring modern decor, cold beverages on tap and a single-cup brewing machine, more packaged takeout options, and dedicated pick-up lines for mobile ordering inside and in the drive-thru. The concept was described as being part of a shift towards becoming an "on-the-go, beverage-led brand". In addition, the location, as well as others, began to trial signage referring to the chain as simply "Dunkin'"—removing "Donuts" from the name. In February 2018, Dunkin' announced plans to phase out polystyrene foam cups globally for environmental purposes by April 2020. In July 2018, Dave Hoffmann took over from Nigel Travis to become the CEO.
Joseph Stalin initially resisted Lenin's proposal but ultimately accepted it, and with Lenin's agreement he changed the name to the Union of Soviet Socialist Republics (USSR), although all republics began as socialist soviet and did not change to the other order until 1936. In addition, in the regional languages of several republics, the word council or conciliar in the respective language was only quite late changed to an adaptation of the Russian soviet and never in others, e.g. Ukrainian SSR. СССР (in the Latin alphabet: SSSR) is the abbreviation of the Russian-language cognate of USSR, as written in Cyrillic letters. The soviets used this abbreviation so frequently that audiences worldwide became familiar with its meaning. After this, the most common Russian initialization is Союз ССР (transliteration: Soyuz SSR) which essentially translates to Union of SSRs in English. In addition, the Russian short form name Советский Союз (transliteration: Sovyetsky Soyuz, which literally means Soviet Union) is also commonly used, but only in its unabbreviated form. Since the start of the Great Patriotic War at the latest, abbreviating the Russian name of the Soviet Union as СС has been taboo, the reason being that СС as a Russian Cyrillic abbreviation is associated with the infamous Schutzstaffel of Nazi Germany, as SS is in English. One apparent exception was the Russian abbreviation of the Communist Party of the Soviet Union, КПСС (transliteration: KPSS). In English-language media, the state was referred to as the Soviet Union or the USSR.
The δ13C of the emu's diet is reflected in the δ13C of the calcite of its egg shell. Small stones are swallowed to assist in the grinding up and digestion of the plant material. Individual stones may weigh 45 g (1.6 oz) and the birds may have as much as 745 g (1.642 lb) in their gizzards at one time. They also eat charcoal, although the reason for this is unclear. Captive emus have been known to eat shards of glass, marbles, car keys, jewellery and nuts and bolts. Emus drink infrequently but ingest large amounts when the opportunity arises. They typically drink once a day, first inspecting the water body and surrounding area in groups before kneeling down at the edge to drink. They prefer being on firm ground while drinking, rather than on rocks or mud, but if they sense danger, they often stand rather than kneel. If not disturbed, they may drink continuously for ten minutes. Due to the scarcity of water sources, emus are sometimes forced to go without water for several days. In the wild, they often share water holes with other animals such as kangaroos; they are wary and tend to wait for the other animals to leave before drinking.
Sources: en.wikipedia.org
==== Education ==== Family, friends, and co-workers of a person with diabetes may provide life-saving treatment in the case of a hypoglycemic episode. It is important for these people to receive training on how to recognize hypoglycemia, what foods to help the hypoglycemic eat, how to administer injectable or intra-nasal glucagon, and how to use a glucose meter.
Estrogens are involved in libido (sex drive) in both women and men. In women, estrogen levels are elevated during the periovulatory period of the menstrual cycle, which is associated with increased sexual motivation. Libido is dependent on androgen levels only in the presence of estrogens. Without estrogens, free testosterone level actually decreases sexual desire. Sexual desire in women who have hypoactive sexual desire disorder can be restored by administration of estrogen (using oral contraceptive). Estrogens are required for female mammals to engage in lordosis behavior during estrus. This behavior is required for sexual receptivity in these mammals and is regulated by the ventromedial nucleus of the hypothalamus.
Diclofenac consumption has been associated with significantly increased vascular and coronary risk in a study including COX-2 inhibitors, diclofenac, ibuprofen and naproxen. Upper gastrointestinal complications were also reported. Major adverse cardiovascular events were increased by about a third by diclofenac, chiefly due to an increase in major coronary events. Compared with placebo, of 1000 patients allocated to diclofenac for a year, three more had major vascular events, one of which was fatal. Vascular death is increased significantly by diclofenac. In October 2020, the US Food and Drug Administration (FDA) required the prescribing information to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in fetuses that result in low amniotic fluid.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。